Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
Por:
Karachaliou, N, Bruno, MF, Bracht, JWP and Rosell, R
Publicada:
1 ene 2019
Ahead of Print:
13 jun 2019
Resumen:
Discovered in 2007, anaplastic lymphoma kinase (ALK) gene rearrangements positive (ALK+) lung cancers compose a small subset of non-small cell lung cancer (NSCLC), with rapidly expanded treatments. There are currently several ALK inhibitors, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib which have been licensed by the US Food and Drug Administration or the European Medicines Agency for the treatment of ALK+ NSCLC patients. Along with the multiple therapies, the survival of this subtype of NSCLC has been significantly expanded, even for patients whose disease has spread in the brain. Alectinib (Alecensa), a specific ALK and rearranged during transfection tyrosine kinase inhibitor is approved as first-line therapy for metastatic ALK+ NSCLC patients. It is additionally approved for ALK+ NSCLC previously treated with crizotinib. The main aim of this review is to assemble on the efficacy of alectinib for the treatment of ALK+ NSCLC, to elaborate the activity of the drug in the central nervous system, and to debate on which is the position of this compound in the treatment course of ALK+ lung cancer patients.
Filiaciones:
Karachaliou, N:
Univ Hosp Sagrat Cor, QuironSalud Grp, IOR, Barcelona, Spain
Quiron Dexeus Univ Inst, Lab Mol Biol, Pangaea Oncol, Mol & Cellular Oncol Lab, Barcelona, Spain
Bruno, MF:
Univ Hosp Sagrat Cor, QuironSalud Grp, IOR, Barcelona, Spain
Bracht, JWP:
Quiron Dexeus Univ Inst, Lab Mol Biol, Pangaea Oncol, Mol & Cellular Oncol Lab, Barcelona, Spain
:
Quiron Dexeus Univ Inst, Lab Mol Biol, Pangaea Oncol, Mol & Cellular Oncol Lab, Barcelona, Spain
Inst Invest Ciencies Germans Trias & Pujol, Badalona, Spain
Hosp Badalona Germans Trias & Pujol, Med Oncol Serv, Catalan Inst Oncol, Badalona, Spain
Quiron Dexeus Univ Inst, Inst Oncol Dr Rosell IOR, Barcelona, Spain
Green Published, Green Submitted, gold
|